FDA Grants Priority Review for Potential New Indication for Lilly's Verzenio(TM) (abemaciclib) as Initial Treatment of Advanced Breast Cancer
INDIANAPOLIS, Oct. 12, 2017 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review designation for its New Drug Application (NDA) for Verz... Biopharmaceuticals, Oncology, FDA Eli Lilly, Verzenio, abemaciclib, breast cancer, metastatic breast cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Grants | Marketing | New Drug Applications | Pharmaceuticals